Shigeru Chiba

List of Publications by Year
in descending order

188 papers	8,463 citations	117571 34 h-index	49868 87 g-index
213 all docs	213 docs citations	213 times ranked	11312 citing authors

#	Article	IF	Citations
1	Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. Journal of Cellular Physiology, 1989, 140, 323-334.	2.0	786
2	A Robust Algorithm for Copy Number Detection Using High-Density Oligonucleotide Single Nucleotide Polymorphism Genotyping Arrays. Cancer Research, 2005, 65, 6071-6079.	0.4	593
3	Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nature Genetics, 2014, 46, 171-175.	9.4	542
4	Frequent inactivation of A20 in B-cell lymphomas. Nature, 2009, 459, 712-716.	13.7	520
5	Notch2 Is Preferentially Expressed in Mature B Cells and Indispensable for Marginal Zone B Lineage Development. Immunity, 2003, 18, 675-685.	6.6	499
6	Notch1 but Not Notch2 Is Essential for Generating Hematopoietic Stem Cells from Endothelial Cells. Immunity, 2003, 18, 699-711.	6.6	416
7	Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature, 2009, 460, 904-908.	13.7	380
8	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
9	Concise Review: Notch Signaling in Stem Cell Systems. Stem Cells, 2006, 24, 2437-2447.	1.4	370
10	Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 2017, 49, 204-212.	9.4	348
11	The oncoprotein Evi-1 represses TGF-Î² signalling by inhibiting Smad3. Nature, 1998, 394, 92-96.	13.7	338
12	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
13	Mouse Jagged1 Physically Interacts with Notch2 and Other Notch Receptors. Journal of Biological Chemistry, 1999, 274, 32961-32969.	1.6	212
14	Binding of Delta1, Jagged1, and Jagged2 to Notch2 Rapidly Induces Cleavage, Nuclear Translocation, and Hyperphosphorylation of Notch2. Molecular and Cellular Biology, 2000, 20, 6913-6922.	1.1	155
15	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia, 2019, 33, 2867-2883.	3.3	148
16	Gainâ€ofâ€function mutations and copy number increases of Notch2 in diffuse large Bâ€cell lymphoma. Cancer Science, 2009, 100, 920-926.	1.7	144
17	Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood, 2016, 127, 596-604.	0.6	98
18	Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia, 2020, 34, 2592-2606.	3.3	91

#	Article	IF	Citations
19	Highly Efficient Ex Vivo Expansion of Human Hematopoietic Stem Cells Using Delta1-Fc Chimeric Protein. Stem Cells, 2006, 24, 2456-2465.	1.4	79
20	Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis. Pigment Cell and Melanoma Research, 2008, 21, 70-78.	1.5	72
21	Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood, 2010, 115, 2872-2881.	0.6	67
22	Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of coactivator p300. Cancer Science, 2005, 96, 274-282.	1.7	65
23	Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nature Communications, 2017, 8, 15068.	5.8	63
24	Clinical significance of diseaseâ€specific <scp>MYD</scp>88 mutations in circulating <scp>DNA</scp> in primary central nervous system lymphoma. Cancer Science, 2018, 109, 225-230.	1.7	57
25	Follow-up of patients with R/R FLT3-mutationâ€“positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood, 2022, 139, 3366-3375.	0.6	55
26	Liquid biopsy for the identification of intravascular large B-cell lymphoma. Haematologica, 2018, 103, e241-e244.	1.7	53
27	Unipotent Megakaryopoietic Pathway Bridging Hematopoietic Stem Cells and Mature Megakaryocytes. Stem Cells, 2015, 33, 2196-2207.	1.4	50
28	c-Maf plays a crucial role for the definitive erythropoiesis that accompanies erythroblastic island formation in the fetal liver. Blood, 2011, 118, 1374-1385.	0.6	49
29	Notch Signaling in Hematopoietic Stem Cells. International Journal of Hematology, 2005, 82, 285-294.	0.7	46
30	Frequent expression of receptors for granulocyte-macrophage colony-stimulating factor on human nonhematopoietic tumor cell lines. Journal of Cellular Physiology, 1990, 143, 483-487.	2.0	43
31	DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease. Blood, 2016, 128, 2846-2858.	0.6	43
32	Dysregulation of TET2 in hematologic malignancies. International Journal of Hematology, 2017, 105, 17-22.	0.7	42
33	MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma. British Journal of Haematology, 2017, 177, 492-494.	1.2	42
34	A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling. Nature Cell Biology, 2022, 24, 565-578.	4.6	42
35	Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. , 1998, 16, 33-37.		38
36	Clinicopathologic Analysis of Angioimmunoblastic T-cell Lymphoma With or Without RHOA G17V Mutation Using Formalin-fixed Paraffin-embedded Sections. American Journal of Surgical Pathology, 2016, 40, 1041-1050.	2.1	38

#	Article	IF	Citations
37	Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. Annals of Hematology, 2017, 96, 1471-1475.	0.8	38
38	D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. Annals of Hematology, 2017, 96, 1641-1652.	0.8	37
39	Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic Tâ€cell lymphoma. Cancer Science, 2018, 109, 490-496.	1.7	37
40	Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. Cancer Research, 2020, 80, 1875-1884.	0.4	36
41	IL-3 specifically inhibits GM-CSF binding to the higher affinity receptor. Journal of Cellular Physiology, 1991, 146, 251-257.	2.0	35
42	Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular responseâ€"The final results of the D-first study. Leukemia Research, 2018, 66, 66-72.	0.4	33
43	Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the Dâ€first study. American Journal of Hematology, 2015, 90, 819-824.	2.0	32
44	Genome-wide surveillance of mismatched alleles for graft-versus-host disease in stem cell transplantation. Blood, 2015, 126, 2752-2763.	0.6	31
45	Primary human herpesvirus 8â€"negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. Blood Advances, 2020, 4, 4442-4450.	2.5	29
46	Dual antitumor mechanisms of Notch signaling inhibitor in a Tâ€cell acute lymphoblastic leukemia xenograft model. Cancer Science, 2009, 100, 2444-2450.	1.7	27
47	Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. International Journal of Hematology, 2016, 104, 548-558.	0.7	27
48	MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis. World Neurosurgery, 2018, 112, e69-e73.	0.7	26
49	Age-Dependent Decrease of DNA Hydroxymethylation in Human T Cells. Journal of Clinical and Experimental Hematopathology: JCEH, 2015, 55, 1-6.	0.3	25
50	Detection of the G17V RHOA Mutation in Angioimmunoblastic T-Cell Lymphoma and Related Lymphomas Using Quantitative Allele-Specific PCR. PLoS ONE, 2014, 9, e109714.	1.1	24
51	Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. International Journal of Hematology, 2011, 93, 618-623.	0.7	23
52	BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. International Journal of Hematology, 2017, 105, 465-469.	0.7	23
53	Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 109-119.	0.3	23
54	Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. International Journal of Hematology, 2016, 103, 53-62.	0.7	21

#	Article	IF	Citations
55	Tet2 deficiency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model. Cancer Science, 2021, 112, 4931-4943.	1.7	21
56	Double somatic mosaic mutations in TET2 and DNMT3Aâ€"origin of peripheral T cell lymphoma in a case. Annals of Hematology, 2015, 94, 1221-1223.	0.8	20
57	G17V RHOA: Genetic evidence of GTP-unbound RHOA playing a role in tumorigenesis in T cells. Small GTPases, 2015, 6, 100-103.	0.7	20
58	Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. Cancer Science, 2019, 110, 401-407.	1.7	20
59	A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma. International Journal of Hematology, 2010, 92, 617-623.	0.7	19
60	Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis. International Journal of Hematology, 2012, 96, 492-500.	0.7	19
61	Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling. Scientific Reports, 2017, 7, 39751.	1.6	18
62	RHOA mutation in follicular Tâ€cell lymphoma: Clinicopathological analysis of 16 cases. Pathology International, 2020, 70, 653-660.	0.6	18
63	Structural and functional analyses of glycosylation on the distinct molecules of human GM-CSF receptors. FEBS Journal, 1991, 198, 659-666.	0.2	17
64	Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. International Journal of Hematology, 2017, 106, 375-384.	0.7	17
65	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. Blood, 2019, 134, 675-675.	0.6	17
66	Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy. American Journal of Hematology, 2001, 66, 85-91.	2.0	16
67	Droplet digital polymerase chain reaction assay and peptide nucleic acidâ€locked nucleic acid clamp method for <scp>RHOA</scp> mutation detection in angioimmunoblastic Tâ€cell lymphoma. Cancer Science, 2018, 109, 1682-1689.	1.7	16
68	Mutations found in cellâ€free DNA s of patients with malignant lymphoma at remission can derive from clonal hematopoiesis. Cancer Science, 2019, 110, 3375-3381.	1.7	16
69	Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes. British Journal of Haematology, 2000, 109, 435-437.	1.2	15
70	High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. Annals of Hematology, 2019, 98, 1031-1032.	0.8	15
71	VAV1 mutations contribute to development of T-cell neoplasms in mice. Blood, 2020, 136, 3018-3032.	0.6	15
72	Diseaseâ€specific mutations in mature lymphoid neoplasms: Recent advances. Cancer Science, 2014, 105, 623-629.	1.7	14

#	Article	IF	Citations
73	Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. Oncology Reports, 2016, 36, 2976-2982.	1.2	14
74	Molecular Pathogenesis of Peripheral T Cell Lymphoma. Current Hematologic Malignancy Reports, 2015, 10, 429-437.	1.2	13
75	Assessment of indomethacin oral spray for the treatment of oropharyngeal mucositis-induced pain during anticancer therapy. Supportive Care in Cancer, 2017, 25, 2997-3000.	1.0	13
76	The Road Map for Megakaryopoietic Lineage from Hematopoietic Stem/Progenitor Cells. Stem Cells Translational Medicine, 2017, 6, 1661-1665.	1.6	13
77	Random Skin Biopsies Before Brain Biopsy for Intravascular Large B-Cell Lymphoma. World Neurosurgery, 2019, 121, e364-e369.	0.7	13
78	Immunogene therapy against mouse leukemia using B7 molecules. Cancer Gene Therapy, 2000, 7, 144-150.	2.2	12
79	Notch2 and Immune Function. Current Topics in Microbiology and Immunology, 2012, 360, 151-161.	0.7	12
80	Increased Serum Soluble Fas Ligand Associated with Recurrent B-Cell Non-Hodgkin's Lymphoma after Autologous Peripheral Blood Stem Cell Transplantation. Leukemia and Lymphoma, 1999, 34, 625-628.	0.6	11
81	Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome. SpringerPlus, 2014, 3, 501.	1.2	11
82	OX40L-JAG1â€“Induced Expansion of Lineage-Stable Regulatory T Cells Involves Noncanonical NF-Î°B Signaling. Journal of Immunology, 2019, 203, 3225-3236.	0.4	11
83	Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status. Blood Advances, 2020, 4, 845-854.	2.5	11
84	Prognosis Factors in Japanese Elderly Patients with Primary Central Nervous System Lymphoma Treated with a Nonradiation, Intermediate-Dose Methotrexate-Containing Regimen. Oncology Research and Treatment, 2014, 37, 378-383.	0.8	10
85	A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 41-46.	0.3	10
86	Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. International Journal of Hematology, 2018, 107, 211-221.	0.7	10
87	A high CD34+ cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors. Bone Marrow Transplantation, 2020, 55, 1726-1735.	1.3	10
88	A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). American Journal of Hematology, 2017, 92, 1324-1332.	2.0	9
89	Treatment of childhoodâ€onset cyclic neutropenia with recombinant human granulocyte colonyâ€stimulating factor. European Journal of Haematology, 1990, 45, 110-111.	1.1	8
90	An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature. Case Reports in Hematology, 2018, 2018, 1-5.	0.3	8

#	Article	IF	Citations
91	Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia. Blood, 2011, 118, 458-458.	0.6	8
92	Effect of stem cell factor (c-kit ligand) on clonogenic leukemic precursor cells: Synergy with other hematopoietic growth factors. American Journal of Hematology, 1994, 47, 328-330.	2.0	7
93	Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Japanese Journal of Clinical Oncology, 2017, 47, 54-60.	0.6	7
94	Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis. International Journal of Hematology, 2018, 108, 447-451.	0.7	7
95	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. Leukemia Research, 2018, 74, 137-143.	0.4	7
96	Frequent but Reversible and Manageable Cardiac Complications after Successful Haploidentical HLA-Mismatched Hematopoietic Stem Cell Transplantation (HSCT) without Ex Vivo Graft Manipulation.. Blood, 2004, 104, 1841-1841.	0.6	7
97	Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia. Blood Cancer Discovery, 2022, 3, 410-427.	2.6	7
98	Marked and reproducible increase in trilineage blood cell counts by administration of granulocyte colony-stimulating factor in a patient with refractory anaemia with excess blasts in transformation. British Journal of Haematology, 1994, 86, 665-667.	1.2	6
99	Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. International Journal of Hematology, 2019, 110, 533-542.	0.7	6
100	Prominence of nestin-expressing Schwann cells in bone marrow of patients with myelodysplastic syndromes with severe fibrosis. International Journal of Hematology, 2019, 109, 309-318.	0.7	6
101	The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse. International Journal of Hematology, 2020, 112, 200-209.	0.7	6
102	Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study. Blood, 2016, 128, 1916-1916.	0.6	6
103	Retrospective analyses of other iatrogenic immunodeficiencyâ€associated lymphoproliferative disorders in patients with rheumatic diseases. British Journal of Haematology, 2021, 195, 585-594.	1.2	5
104	Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. International Journal of Hematology, 2022, 116, 228-238.	0.7	5
105	QUANTITATION OF HEPATITIS G VIRUS RNA IN ALLOGENEIC BONE MARROW TRANSPLANT RECIPIENTS. British Journal of Haematology, 1998, 100, 798-799.	1.2	4
106	Serial serum thrombopoietin levels in a pregnant woman with essential thrombocythaemia.. British Journal of Haematology, 1999, 105, 271-273.	1.2	4
107	Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum. International Journal of Hematology, 2010, 92, 474-480.	0.7	4
108	A nationwide survey of co-occurrence of malignant lymphomas and myelodysplastic syndromes/myeloproliferative neoplasms. Annals of Hematology, 2016, 95, 829-830.	0.8	4

#	Article	IF	Citations
109	Progression to polythythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation. Annals of Hematology, 2018, 97, 737-739.	0.8	4
110	In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations. Blood, 2014, 124, 823-823.	0.6	4
111	The prognosis of disseminated intravascular coagulation associated with hematologic malignancy and its response to recombinant human thrombomodulin. Thrombosis Research, 2019, 173, 57-64.	0.8	3
112	A simple HPLC assay for determining eltrombopag concentration in human serum. Biomedical Chromatography, 2021, 35, e5049.	0.8	3
113	Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category. Journal of Clinical and Experimental Hematopathology: JCEH, 2021, 61, 61-70.	0.3	3
114	Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry). Journal of Clinical Medicine, 2021, 10, 1370.	1.0	3
115	Intratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples. Cancer Science, 2022, 113, 362-364.	1.7	3
116	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. Blood, 2020, 136, 17-18.	0.6	3
117	Binding Properties and Proliferative Effects of Human Recombinant Granulocyte-Macrophage Colony-stimulating Factor in Primary Leukemia and Lymphoma. Japanese Journal of Cancer Research, 1989, 80, 887-894.	1.7	2
118	Long-Term Third Chronic Phase of Chronic Myelogenous Leukemia Maintained by Interferon-Î± and Methotrexate. Leukemia and Lymphoma, 1999, 33, 193-197.	0.6	2
119	Prolonged Survival of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with Umbilical Cord Blood following a Second Relapse. Case Reports in Hematology, 2014, 2014, 1-3.	0.3	2
120	Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab. Annals of Hematology, 2015, 94, 2061-2062.	0.8	2
121	Notch Signaling in Nestin-Expressing Cells in the Bone Marrow Maintains Erythropoiesis via Macrophage Integrity. Stem Cells, 2019, 37, 924-936.	1.4	2
122	Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide. Annals of Hematology, 2021, 100, 1295-1301.	0.8	2
123	Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial. Blood, 2019, 134, 845-845.	0.6	2
124	Distinct, Ethnic, Clinical, and Genetic Characteristics of Myelodysplastic Syndromes with Der(1;7). Blood, 2019, 134, 5392-5392.	0.6	2
125	Genome-Wide Analysis of MDS/MPD Disclosed Frequent Homozygous C-Cbl mutations Tightly Associated with 11q-UPD. Blood, 2008, 112, 855-855.	0.6	2
126	Mutational Spectrum Analysis of Interesting Correlation and Interrelationship Between RNA Splicing Pathway and Commonly Targeted Genes in Myelodysplastic Syndrome. Blood, 2011, 118, 273-273.	0.6	2

#	Article	IF	Citations
127	Peripherally Inserted Central Catheters Are a Good Option For Venous Access In The Patients With Hematologic Diseases. Blood, 2013, 122, 2956-2956.	0.6	2
128	Clinical â€œMUTATOMEâ€•Of Myelodysplastic Syndrome; Comparison To Primary Acute Myelogenous Leukemia. Blood, 2013, 122, 518-518.	0.6	2
129	Somatic G17V Rhoa Mutation Specifies Angioimmunoblastic T-Cell Lymphoma. Blood, 2013, 122, 815-815.	0.6	2
130	NGS-Based Copy Number Analysis in 1,185 Patients with Myeloid Neoplasms. Blood, 2016, 128, 955-955.	0.6	2
131	Whole-Genome Sequencing of Primary Central Nervous System Lymphoma and Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 4112-4112.	0.6	2
132	EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. Blood, 2021, 138, 610-610.	0.6	2
133	Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms. Blood, 2021, 138, 1513-1513.	0.6	2
134	A case of solitary plasmacytoma of bone showing co-expression of both immunoglobulin light chains. European Journal of Medical Research, 2021, 26, 148.	0.9	2
135	Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events. Journal of Clinical and Experimental Hematopathology: JCEH, 2022, , .	0.3	2
136	Nine years interval between first and second bone marrow transplantations and subsequent long-term survivalâ€”a case of acute myeloid leukemia with MLL-AF6 fusion gene. Annals of Hematology, 2012, 91, 1491-1493.	0.8	1
137	Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. Case Reports in Hematology, 2015, 2015, 1-4.	0.3	1
138	Guest editorial: pre-leukemia/pre-lymphomaâ€”what is old, what is new?. International Journal of Hematology, 2015, 102, 511-512.	0.7	1
139	â€œSleep epileptologyâ€â€”a new field of sleep medicine and epileptology. Sleep and Biological Rhythms, 2019, 17, 1-2.	0.5	1
140	Aggressive conjunctival carcinoma arising on poorly controlled sun-damaged graft-versus-host disease. European Journal of Dermatology, 2020, 30, 313-314.	0.3	1
141	Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematological Oncology, 1998, 16, 33-37.	0.8	1
142	First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) â€“ A Systematic Review and Individual Patient Data Meta-Analysis. Blood, 2012, 120, 3655-3655.	0.6	1
143	Baseline Assessment Of GPI-Anchored Protein Deficient Blood Cells In Patients With Bone Marrow Failure (The OPTIMA study). Blood, 2013, 122, 1241-1241.	0.6	1
144	Hypermethylation of Bcl6 Is a Potential Cause of Development of Lymphoma with Tfh Features in Tet2 Knockdown Mice. Blood, 2013, 122, 2490-2490.	0.6	1

#	Article	IF	Citations
145	Genome-Wide Association Studies of Genetic Incompatibility That Is Relevant to the Development of GvHD in Unrelated Bone Marrow Transplantation. Blood, 2008, 112, 715-715.	0.6	1
146	Recurrent Mutations of Multiple Components of Cohesin Complex in Myeloid Neoplasms. Blood, 2012, 120, 782-782.	0.6	1
147	Abnormal Increase in a Distinct Subset of Nestin-Expressing Cells in the Bone Marrow of Myelodysplastic Syndromes. Blood, 2016, 128, 3887-3887.	0.6	1
148	Recurrent VAV1 Abnormalities in Angioimmunoblastic T Cell Lymphoma. Blood, 2016, 128, 4104-4104.	0.6	1
149	Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure. Internal Medicine, 2022, , .	0.3	1
150	S100a8/S100a9-Emmprin-Vegfa Axis Initiated By Tet2-Deficient Immune Cells Exacerbates Lung Cancer Progression through Promotion of Angiogenesis. Blood, 2021, 138, 3276-3276.	0.6	1
151	Cardiac Tamponade as a Recurrence of Angioimmunoblastic T-Cell Lymphoma with the Detection of a p.Gly17Val RHOA Mutation in the Pericardial Effusion. Internal Medicine, 2023, 62, 595-600.	0.3	1
152	Circulating late-stage erythroid progenitors in a patient with agnagenic myeloid metaplasia. American Journal of Hematology, 1994, 45, 194-195.	2.0	0
153	Investigation of new feature vectors to improve an automatic classification accuracy of granulocyte. , 2017, , .		0
154	Development of automatic classification system for leukocyte images using Random Forest. Electronics and Communications in Japan, 2018, 101, 13-19.	0.3	0
155	Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Case Reports in Hematology, 2019, 2019, 1-5.	0.3	0
156	Ki23819 (KRN383â€¢HCl) Inhibits Kinase Activity of Wild Type and Mutant FLT3 Receptor Tyrosine Kinase In Vitro.. Blood, 2004, 104, 1168-1168.	0.6	0
157	Genome-Wide Analysis of Copy Number Alterations/LOH/Allelic Imbalances in Non-Hodgkin Lymphoma Using Ultrahigh-Density SNP-Genotyping Microarrays with the Robust CNAG Algorithms.. Blood, 2005, 106, 420-420.	0.6	0
158	Genome-Wide Analysis of Copy Number Analysis of Myelodysplastic Syndromes Using High-Density SNP-Genotyping Microarrays.. Blood, 2005, 106, 3420-3420.	0.6	0
159	Exploring Genetic Basis of GVHD by Whole-Genome Association Studies in a Large Series from the Japan Marrow Donation Program (JMDP).. Blood, 2007, 110, 3232-3232.	0.6	0
160	Implication of AML1/RUNX1 Function in the Homeostasis and Leukemic Transformation of Hematopoietic Stem Cells.. Blood, 2007, 110, 4117-4117.	0.6	0
161	Whole Exome Analysis of Myelodysplastic Syndromes Using Next-Generation Resequencing Technology. Blood, 2010, 116, 295-295.	0.6	0
162	Profiling of Multiple Gene Mutations In Myelodysplastic Syndromes Using High-Throughput Resequenceing Combined with Barcode Labeling. Blood, 2010, 116, 4011-4011.	0.6	0

#	Article	IF	Citations
163	Detection of CD55- and CD59-Negative Immature Reticulocytes May Improves Sensitivity/Specificity to Identify a Minor Population of PNH-Type Cells in Patients with Myelodysplastic Syndrome/Aplastic Anemia. Blood, 2011, 118, 4373-4373.	0.6	0
164	Functional Analysis of SRSF2 Mutations in Myelodysplastic Syndromes and Related Disorders. Blood, 2011, 118, 1706-1706.	0.6	0
165	Transcription Factor Hes1 Functions As a Tumor Suppressor in MLL-Associated Acute Leukemia. Blood, 2012, 120, 118-118.	0.6	0
166	Implication of the Distinct Differentiation Pathway of Megakaryocytes From Hematopoietic Stem Cells in the Mouse Bone Marrow. Blood, 2012, 120, 1204-1204.	0.6	0
167	Soluble Recombinant Thrombomodulin Is a Potentially Promising Agent without Causing Severe Hemorrhagic Events for Hematological Malignancy-Induced Disseminated Intravascular Coagulation. Blood, 2012, 120, 3413-3413.	0.6	0
168	Hes1 Is Responsible For Notch Signaling-Mediated Suppression Of Acute Myeloid Leukemia Development Via Suppression Of FLT3 Expression. Blood, 2013, 122, 3800-3800.	0.6	0
169	Recombinant Thrombomodurin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 5454-5454.	0.6	0
170	A Novel Diagnostic Method For AITL By Detecting RHOA G17V Hotspot Mutation Using Allele-Specific Real-Time PCR. Blood, 2013, 122, 3000-3000.	0.6	0
171	Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant Therapy Without Causing Severe Hemorrhagic Events. Blood, 2013, 122, 2381-2381.	0.6	0
172	Novel Biological Effects and Distinct Patterns of Rhoa Mutations in Adult T-Cell Leukemia/Lymphoma and Angioimmunoblastic T Cell Lymphoma. Blood, 2014, 124, 2215-2215.	0.6	0
173	Notch Signaling in Bone Marrow Nestin-Expressing Cells Controls Balance of Erythropoiesis at the Bone Marrow and Spleen. Blood, 2016, 128, 432-432.	0.6	0
174	Genetic Landscape and Clonal Evolution Following 5-Aza Therapy in Patients with High-Risk Myelodysplastic Syndromes. Blood, 2016, 128, 4304-4304.	0.6	0
175	Integrated Molecular Analysis of Myelodysplastic Syndromes Using Whole Genome Sequencing. Blood, 2016, 128, 5512-5512.	0.6	0
176	Foxp3+ regulatory T Cells Maintain Bone Marrow Microenvironment for B Cell Differentiation from Hematopoietic Stem Cells. Blood, 2016, 128, 431-431.	0.6	0
177	Analysis of the Prevalence and Risk Factors of Adult Neutropenia in a Large Cohort in Japan. Blood, 2016, 128, 4738-4738.	0.6	0
178	Targeting Complete Response with Upfront Bortezomib Followed By Autologous Transplantation and Consolidation Therapy for Untreated Multiple Myeloma (TUBA study). Blood, 2016, 128, 3463-3463.	0.6	0
179	Association of Increased Ring Ssideroblasts with Inferior Survival in Patients with Myelodysplastic Syndrome with Multi-Lineage Dysplasia. Blood, 2016, 128, 5530-5530.	0.6	0
180	the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes. Blood, 2016, 128, 4287-4287.	0.6	0

#	Article	IF	Citations
181	NOTCH in Malignant Lymphoma. , 2017, , 79-92.		0
182	Analysis of Genomic Predispositions to Sporadic Myeloid Neoplasms Mediated By DDX41 in Japan. Blood, 2018, 132, 4371-4371.	0.6	0
183	Genome-Wide Analysis of Non-Coding Alterations in Pan-Myeloid Cancers Using Whole Genome Sequencing. Blood, 2018, 132, 103-103.	0.6	0
184	Distinct Bone Marrow Microenvironment Abnormalities in MDS and MPN with Fibrosis. Blood, 2019, 134, 2976-2976.	0.6	0
185	Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms. Blood, 2019, 134, 4216-4216.	0.6	0
186	An overlapping case of <i>in situ</i> mantle cell neoplasia and leukemic non-nodal mantle cell lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 169-173.	0.3	0
187	Germinal Center B Cells Derived from TET2-Mutated Clonal Hematopoiesis Provide a Microenviromental Niche for Tumor Cells in Angioimmunoblastic T-Cell Lymphoma. Blood, 2021, 138, 445-445.	0.6	0
188	A Single-Cell Atlas of Nonhematopoietic Cells in Human Lymph Node and Lymphoma Reveals Landscape of Stromal Remodeling. Blood, 2021, 138, 447-447.	0.6	0